Integrated Filing — IndAS



General information about company
Scrip Code 540975
NSE Symbol ASTERDM
MSEI Symbol NOTLISTED
ISIN INE914M01019
Name of company Aster DM Healthcare Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2025
Date of end of financial year 31-Mar-2026
Date of board meeting when results were approved 30-Jul-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 25-Jul-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter First quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 30-Jul-2025   11:10:00
End date and time of board meeting 30-Jul-2025   16:46:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 10778700000
Other income 331800000
Total income 11110500000
2 Expenses
(a) Cost of materials consumed 0
(b) Purchases of stock-in-trade 2471500000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -100000
(d) Employee benefit expense 1948100000
(e) Finance costs 307700000
(f) Depreciation, depletion and amortisation expense 632200000
(f) Other Expenses
1 Professional fees to consultant doctors 2397000000 2397000000
2 Laboratory outsourcing charges 77600000 77600000
3 Other expenses 1811000000 1811000000
4 0 0 0
5 0 0 0
6 0 0 0
7 0 0 0
8 0 0 0
9 0 0 0
10 0 0 0
Total other expenses 4285600000
Total expenses 9645000000
3 Total profit before exceptional items and tax 1465500000
4 Exceptional items -43900000
5 Total profit before tax 1421600000
6 Tax expense
7 Current tax 439800000
8 Deferred tax -11000000
9 Total tax expenses 428800000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0
11 Net Profit Loss for the period from continuing operations 992800000
12 Profit (loss) from discontinued operations before tax 0
13 Tax expense of discontinued operations 0
14 Net profit (loss) from discontinued operation after tax 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method -57200000
16 Total profit (loss) for period 935600000
17 Other comprehensive income net of taxes -4000000
18 Total Comprehensive Income for the period 931600000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 855200000
Total profit or loss, attributable to non-controlling interests 80400000
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 851200000
Total comprehensive income for the period attributable to owners of parent non-controlling interests 80400000
21 Details of equity share capital
Paid-up equity share capital 5181300000
Face value of equity share capital 10
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 1.67
Diluted earnings (loss) per share from continuing operations 1.67
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0
Diluted earnings (loss) per share from discontinued operations 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 1.67
Diluted earnings (loss) per share from continuing and discontinued operations 1.67
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2025
Date of end of reporting period 30-Jun-2025
Whether accounts are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Hospitals 10469500000 10469500000
2 Clinics 72600000 72600000
3 Wholesale Pharmacies 206100000 206100000
4 Others 30500000 30500000
5 0 0 0
6 0 0 0
7 0 0 0
8 0 0 0
9 0 0 0
10 0 0 0
11 0 0 0
12 0 0 0
13 0 0 0
14 0 0 0
15 0 0 0
Total Segment Revenue 10778700000
Less: Inter segment revenue 0 0
Revenue from operations 10778700000
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Hospitals 1853200000 1853200000
2 Clinics -21800000 -21800000
3 Wholesale Pharmacies -86100000 -86100000
4 Others -59900000 -59900000
5 0 0 0
6 0 0 0
7 0 0 0
8 0 0 0
9 0 0 0
10 0 0 0
11 0 0 0
12 0 0 0
13 0 0 0
14 0 0 0
15 0 0 0
Total Profit before tax 1685400000
i. Finance cost 307700000 307700000
ii. Other Unallocable Expenditure net off Unallocable income 13300000 13300000
Profit before tax 1364400000
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Hospitals 62235800000 62235800000
2 Clinics 171400000 171400000
3 Wholesale Pharmacies 560600000 560600000
4 Others 250000000 250000000
5 0 0 0
6 0 0 0
7 0 0 0
8 0 0 0
9 0 0 0
10 0 0 0
11 0 0 0
12 0 0 0
13 0 0 0
14 0 0 0
15 0 0 0
Total Segment Asset 63217800000 63217800000
Un-allocable Assets 14659800000 14659800000
Net Segment Asset 77877600000 77877600000
4 Segment Liabilities
Segment Liabilities
1 Hospitals 28980400000 28980400000
2 Clinics 106800000 106800000
3 Wholesale Pharmacies 278900000 278900000
4 Others 0 0
5 0 0 0
6 0 0 0
7 0 0 0
8 0 0 0
9 0 0 0
10 0 0 0
11 0 0 0
12 0 0 0
13 0 0 0
14 0 0 0
15 0 0 0
Total Segment Liabilities 29366100000 29366100000
Un-allocable Liabilities 1509500000 1509500000
Net Segment Liabilities 30875600000 30875600000
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2025
B Date of end of reporting period 30-Jun-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss
3 Amount of items that will be reclassified to profit and loss
1 Exchange difference in translating financial statements of foreign operations -5400000 -5400000
Total Amount of items that will be reclassified to profit and loss -5400000
4 Income tax relating to items that will be reclassified to profit or loss -1400000
5 Total Other comprehensive income -4000000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 M/S Deloitte Haskins & Sells Yes 30-Apr-2028